monosialotetrahexosyl ganglioside

Small moleculeexperimental

Clinical trial activity

9 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
9
Phase 3
6
Phase 4
0

Earliest trial started Nov 1, 1999 (NCT00037830)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • monosialotetrahexosylganglioside
  • monosialotetrahexosylganglioside
  • monosialotetrahexosyl ganglioside
  • monosialotetrahexosylganglioside sodium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05751668Phase 2May 31, 2023National Cancer Institute (NCI)
NCT04395339Phase 3May 15, 2020Sun Yat-Sen University
NCT02468739Phase 3May 1, 2015Sun Yat-Sen University
NCT02486198Phase 3May 1, 2015Nanjing Medical University, Tianjin Medical University
NCT02251977Phase 3Sep 1, 2014Sun Yat-Sen University
NCT02093910Phase 2Apr 1, 2014Sun Yat-Sen University
NCT02024438Phase 3Dec 1, 2013Nanjing Medical University, Tianjin Medical University
NCT02024412Phase 3Nov 1, 2013Nanjing Medical University, Tianjin Medical University
NCT00037830Phase 2Nov 1, 1999National Institute of Neurological Disorders and Stroke (NINDS), Thomas Jefferson University
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sun Yat-Sen UniversityAcademic/Hospital4422014
Nanjing Medical UniversityAcademic/Hospital3312013
Tianjin Medical UniversityAcademic/Hospital3012013
National Cancer Institute (NCI)Government1112023
National Institute of Neurological Disorders and Stroke (NINDS)Government1011999
Thomas Jefferson UniversityAcademic/Hospital1111999
6 organizations
Page 1 / 1